Bionano Genomics EBIT per Share
The EBIT per Share of Bionano Genomics (BNGO) as of Oct 20, 2026 is -3.10 USD. In the previous year, EBIT per Share was -59.05 USD — a change of -94.74% (higher).
Get this data via API
Financial Data API
EBIT per Share
-3.10USD
YoY
-94.74%
Last updated:
The Bionano Genomics EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.31USD | +451.16% |
| est | 0.06USD | -164.04% |
| est | -0.09USD | -72.50% |
| est | -0.31USD | -65.34% |
| est | -0.91USD | -70.75% |
| -3.10USD | -94.74% | |
| -59.05USD | -80.19% | |
| -298.11USD | +12.12% | |
| -265.90USD | +61.37% | |
| -164.78USD | +4,351.71% | |
| -3.70USD | -99.23% | |
| -482.12USD | -60.33% | |
| -1,215.18USD | +27,814.76% | |
| -4.35USD | +137.44% | |
| -1.83USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bionano Genomics Stock analysis
Frequently Asked Questions about Bionano Genomics stock
EBIT per Share of Bionano Genomics is -3.10 USD in 2025.
EBIT per Share of Bionano Genomics changed from -59.05 USD to -3.10 USD, representing a -94.74% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Bionano Genomics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Bionano Genomics
All Key Metrics — Bionano Genomics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth